What is EYPT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for EYPT?

P/E (TTM) is n/a and 52-week range is $0.34 to $19.11 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s EYPT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for EYPT?

The company profile lists revenue (TTM) near $3M, net income (TTM) near -$30.52B, EPS (TTM) near -$3.74 when available from the market-data feed. Figures are informational and may lag live markets.

Where is EyePoint Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Watertown, Massachusetts, US, 86.2M shares outstanding, ISIN US30233G2093 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

EyePoint Inc

$EYPT

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 214 full-time employees. The company went IPO on 2005-01-27. The firm is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Employees

214

Website

eyepoint.bio/

IPO

2005-01-27

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US30233G2093

Headquarters

Watertown, Massachusetts, US

Shares outstanding

86.2M

NAICS sector

Manufacturing

Institutional ownership

109.46%

Browse other companiesFree AI scores and summaries for more stocks